The estimated Net Worth of Charles P Jr Waite is at least $38.2 Million dollars as of 6 May 2024. Mr. Waite owns over 41,133 units of Nanostring Technologies Inc stock worth over $8,349 and over the last 11 years he sold NSTG stock worth over $37,950,118. In addition, he makes $207,479 as Independent Director at Nanostring Technologies Inc.
Charles has made over 31 trades of the Nanostring Technologies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 41,133 units of NSTG stock worth $4,331 on 6 May 2024.
The largest trade he's ever made was selling 588,024 units of Nanostring Technologies Inc stock on 21 November 2016 worth over $12,495,510. On average, Charles trades about 54,546 units every 84 days since 2013. As of 6 May 2024 he still owns at least 79,284 units of Nanostring Technologies Inc stock.
You can see the complete history of Mr. Waite stock trades at the bottom of the page.
Charles P. (Chad) Waite Jr. is an Independent Director of the Company. He has been a General Partner of OVP Venture Partners II and a Vice President of Northwest Venture Services Corp. since 1987, a General Partner of OVP Venture Partners III since 1994, a General Partner of OVP Venture Partners IV since 1997, a General Partner of OVP Venture Partners V since 2000, a General Partner of OVP Venture Partners VI since 2001, and a General Partner of OVP Venture Partners VII since 2007, all of which are venture capital firms. Prior to joining OVP, Mr. Waite was a General Partner at Hambrecht & Quist Venture Partners from 1984 to 1988, where he focused on investments in information technology and life sciences. He is a former director of Complete Genomics, a publicly-traded DNA sequencing platform developer (acquired by BGI-Shenzen in March 2013), and currently serves on the board of directors of eight private companies. Mr. Waite received an A.B. in history from Kenyon College and an M.B.A. from Harvard University. Mr. Waite’s investment focus on life sciences companies also provides substantial expertise in our industry.
As the Independent Director of Nanostring Technologies Inc, the total compensation of Charles Waite at Nanostring Technologies Inc is $207,479. There are 13 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of $7,288,840.
Charles Waite is 64, he's been the Independent Director of Nanostring Technologies Inc since 2004. There are 2 older and 16 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
Charles's mailing address filed with the SEC is 530 FAIRVIEW AVENUE N, , SEATTLE, WA, 98109.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus..., and Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: